Rakovina Therapeutics Inc. RKV.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -62.88% | -62.07% | 49.74% | 100.05% | 334.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.07% | -26.85% | 29.33% | 72.35% | 269.63% |
| Operating Income | 44.07% | 26.85% | -29.33% | -72.35% | -269.63% |
| Income Before Tax | 40.79% | 19.59% | -27.75% | -74.48% | -251.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.79% | 19.59% | -27.75% | -74.48% | -251.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.79% | 19.59% | -27.75% | -74.48% | -251.50% |
| EBIT | 44.07% | 26.85% | -29.33% | -72.35% | -269.63% |
| EBITDA | 46.45% | 29.06% | -32.31% | -84.62% | -327.79% |
| EPS Basic | 61.43% | 48.84% | 39.59% | 26.00% | -56.25% |
| Normalized Basic EPS | 61.35% | 51.78% | 38.17% | 26.11% | -56.23% |
| EPS Diluted | 61.43% | 45.97% | 39.59% | 26.00% | -51.08% |
| Normalized Diluted EPS | 61.35% | 51.78% | 38.17% | 26.11% | -56.23% |
| Average Basic Shares Outstanding | 53.45% | 57.19% | 111.36% | 135.85% | 125.00% |
| Average Diluted Shares Outstanding | 53.45% | 57.19% | 111.36% | 135.85% | 125.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |